“There is, in a way, a greater therapeutic deficit for women with heart failure than for men with heart failure because women are more afflicted by the HFpEF phenotype.” McMurray, MD, professor of cardiology at the Institute of Cardiovascular and Medical Sciences at University of Glasgow in Scotland, said during the press conference. “We don’t have any effective treatments for, and that is the type of heart failure that affects women more than the other major phenotype, HFrEF, which is more of a male disease,” John J.V. In this analysis, researchers analyzed data from 2,479 women (mean age, 74 years mean LVEF, 59%) and 2,317 men (mean age, 72 years mean LVEF, 56%). In the subgroup analyses of the trial, only sex and left ventricular ejection fraction modified the effect of sacubitril/valsartan compared with valsartan alone for the primary outcome, which was CV death and total first and recurrent HF hospitalizations. Both analyses were simultaneously published in Circulation.Īs Healio previously reported at the European Society of Cardiology Congress in September, sacubitril/valsartan (Entresto, Novartis) did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved ejection fraction, defined as at least 45%. The sex difference was not observed for quality of life, NYHA class and worsening renal function, according to the researchers.
#Paragon trial trial#
PHILADELPHIA - Sacubitril/valsartan reduced the risk for HF hospitalization more in women compared with men, and the overall benefit of sacubitril/valsartan was driven by a benefit in patients with chronic HF and a left ventricular ejection fraction below the normal range, according to two analyses of the PARAGON-HF trial of patients with HF with preserved EF presented at the American Heart Association Scientific Sessions.
0 kommentar(er)
